premique 0.625mg/5mg coated tablets
pfizer healthcare ireland - conjugated estrogens; medroxyprogesterone acetate - coated tablet - 0.625mg/5m percent volume/volume - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen
premarin 0.625 milligram tablet prolonged release
b & s healthcare - estrogens conjugated - tablet prolonged release - 0.625 milligram - natural and semisynthetic estrogens, plain
premarin 1.25 milligram tablet prolonged release
b & s healthcare - estrogens conjugated - tablet prolonged release - 1.25 milligram - natural and semisynthetic estrogens, plain
premplus kit
pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 2.5mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 2.5mg - estrogens
premplus kit
pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 5mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 5mg - estrogens
premplus cycle kit
pfizer canada ulc - conjugated estrogens; medroxyprogesterone acetate - kit - 0.625mg; 10mg - conjugated estrogens 0.625mg; medroxyprogesterone acetate 10mg - estrogens
prempak-c 0.625mg/0.15mg coated tablets
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - norgestrel, estrogens conjugated - coated tablet - norgestrel 0.15 mg estrogens conjugated 0.625 mg - sex hormones and modulators of the genital system
covaryx hs- estrogens, esterified and methyltestosterone tablet, coated covaryx- estrogens, esterified and methyltestosterone t
centrix pharmaceutical, inc, - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, esterified 1.25 mg - covaryxt® and covaryx® h.s. are indicated in the treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) covaryxt® and covaryx® h.s. have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus (see boxed warnings). estrogens should not be used in women with any of the following conditions: - known or suspected cancer of the breast except in appropriately selected patients being treated for metastatic disease. - known or suspected estrogen-dependent neoplasia. - known or suspected pregnancy (see boxed warnings). - undiagnosed abnormal genital bleeding. - active thrombophlebitis or thromboembolic disorders. - a past history of thrombophlebitis, thrombosis, or thromboembolic disorders associated with previ
prempak-c 1.25mg/0.15mg coated tablets
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - norgestrel, estrogens conjugated - coated tablet - norgestrel 0.15 mg estrogens conjugated 1.25 mg - sex hormones and modulators of the genital system
duavive
pfizer new zealand limited - bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat; ; conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core); - modified release tablet - 0.45mg/20mg - active: bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core) excipient: ascorbic acid hyprolose hypromellose isopropyl alcohol lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose opacode black ns-78-17821 opadry pink 03b14899 opaglos clear 98z19173 purified water sucrose sucrose palmitate - duavive is indicated for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. the experience treating women older than 65 years is limited.